IL-4 and IL-13: Their Role in Allergy and Immunity

IL-4 and IL-13 are two closely related immune-signaling proteins that act as central drivers of allergic inflammation and broader type 2 immunity. They share a receptor subunit, activate overlapping signaling pathways, and cooperate in processes like IgE antibody production and mucus secretion. Yet they are not simply redundant copies of each other. IL-4 has a unique grip on T cell development that IL-13 cannot replicate, while IL-13 dominates tissue-level changes in the lungs, gut, and skin that make allergic disease so physically miserable. Understanding how they divide labor, and where they overlap, explains both why allergies happen and how modern biologic drugs work to treat them.

Two Cytokines, One Shared Receptor Chain

IL-4 and IL-13 genes sit near each other on chromosome 5 and share key regulatory sequences in their promoters, which helps explain why the same immune cells tend to produce both of them at once.¹ Both are released primarily by activated T helper 2 (Th2) cells and mast cells, with additional contributions from innate lymphoid cells, basophils, and eosinophils.

The signaling architecture is where their relationship gets interesting. IL-4 can signal through two different receptor complexes. The first, known as the type I receptor, pairs the IL-4Rα chain with the common gamma chain and is found mainly on immune cells like T and B lymphocytes. The second, the type II receptor, pairs IL-4Rα with IL-13Rα1 and is expressed on a much wider range of cell types, including epithelial cells, smooth muscle cells, and fibroblasts. IL-13 signals exclusively through this type II receptor: it first binds IL-13Rα1 with moderate affinity, then recruits the IL-4Rα chain to complete the complex.² Because both cytokines use IL-4Rα as part of their signaling machinery, they activate the same downstream transcription factor, STAT6, which accounts for much of their functional overlap.

The critical difference is that T cells express the common gamma chain but generally lack IL-13Rα1. This means IL-13 cannot directly act on T cells, while IL-4 can.¹ That single receptor-distribution detail has enormous consequences: IL-4 steers naïve T cells toward becoming Th2 cells in the first place, establishing the very immune profile that then produces both IL-4 and IL-13 in large quantities. IL-13 arrives at the scene without the ability to recruit new Th2 cells but with powerful effects on the tissues those cells are defending or, in the case of allergies, attacking.

Launching the Th2 Response

Before IL-4 and IL-13 can do anything in an allergic reaction, the immune system has to decide to mount a Th2-type response rather than some other kind. IL-4 is the linchpin of that decision. When a naïve T cell encounters an antigen and begins activating, early IL-4 production pushes it down the Th2 developmental pathway. This early burst of IL-4 depends on T cell receptor signaling and the transcription factor GATA-3, with IL-2 receptor signaling also playing a supporting role.³ Once a critical mass of Th2 cells exists, they produce IL-4 and IL-13 together, creating a self-reinforcing loop that sustains and amplifies the type 2 immune environment.

IL-13 plays no part in this initial T cell commitment step. Its absence from T cell biology is one reason researchers sometimes describe IL-4 as the “upstream” cytokine and IL-13 as more of an “effector” cytokine, one that acts on tissues once the Th2 machinery is already running.

IgE Production and the Allergic Cascade

One of the most clinically important things IL-4 and IL-13 do together is tell B cells to produce immunoglobulin E (IgE), the antibody class responsible for immediate allergic reactions. When IgE binds to mast cells and then encounters its target allergen, the mast cells release histamine and other inflammatory mediators, producing the familiar symptoms of hay fever, hives, and anaphylaxis.

Both IL-4 and IL-13 can independently drive B cells to switch their antibody production to IgE and IgG4. IL-13 does this by activating the same germline IgE gene transcription that IL-4 activates, directing naïve B cells to undergo class switching.⁴ Studies comparing atopic and non-atopic individuals have found that the B cell compartment itself is not inherently different between the two groups; rather, the difference lies in the cytokine signals those B cells receive. When B cells from either group were activated with IL-4 or IL-13, they produced comparable amounts of IgE.⁵ The allergy problem, in other words, is not faulty B cells but an immune environment saturated with the wrong cytokines.

What They Do to Airway Tissue

If IgE is the trigger that fires off an acute allergic reaction, IL-4 and IL-13 are the architects of the chronic tissue changes that make diseases like asthma so persistent. Their effects on the airways are multi-layered and, in severe disease, physically remodel the lung.

The first layer is the epithelial barrier. Airway epithelial cells are joined by tight junction proteins that control what passes between them. Both IL-4 and IL-13 weaken these junctions, reducing electrical resistance across the cell layer and increasing the leakage of molecules through gaps between cells.⁶ Research into how IL-13 accomplishes this has shown that it triggers the tagging and degradation of tight junction proteins through the ubiquitin-proteasome system, essentially marking those structural proteins for disposal. Blocking the JAK/STAT signaling pathway prevented IL-13 from doing this, confirming the connection back to the receptor system described earlier.⁷ A leaky barrier means allergens, pollutants, and pathogens penetrate deeper into the tissue, worsening inflammation.

The second layer is mucus overproduction. IL-13 drives airway epithelial cells to transform into mucus-secreting goblet cells, a process called goblet cell hyperplasia. In lab-grown human bronchial tissue, even modest concentrations of IL-13 increased goblet cell density by five- to tenfold.⁸ This expansion of goblet cells is tied to upregulation of the mucin gene MUC5AC, which produces the thick, sticky mucus that clogs airways in asthma.⁹

The third layer is airway hyperresponsiveness, the exaggerated twitchiness of airway smooth muscle that characterizes asthma. IL-13 and IL-4 both make isolated human small airways more sensitive to contractile signals like histamine and leukotrienes, while other inflammatory cytokines such as IL-5 and IL-17A do not produce the same effect.¹⁰ At the cellular level, IL-13 boosts the expression of histamine and leukotriene receptors on smooth muscle cells and enhances calcium signaling, making the muscle contract more forcefully when provoked.¹¹ Together, these three tissue-level changes, a leaky barrier, excess mucus, and twitchy smooth muscle, explain why chronic asthma feels like breathing through a wet, narrowing straw.

The Evolutionary Reason They Exist

Allergies are a misfiring of an immune program that evolved for a real purpose: expelling parasitic worms. Helminths are large, multicellular invaders that cannot be killed by the same mechanisms the body uses against bacteria or viruses. The type 2 immune response, orchestrated by IL-4, IL-13, and related cytokines, drives a coordinated strategy sometimes called “weep and sweep.” Increased mucus secretion and fluid flow (“weep”) combined with enhanced smooth muscle contraction and gut motility (“sweep”) physically dislodge worms from tissue surfaces and push them out of the intestine.¹²

This response also includes tissue repair and tolerance mechanisms at the sites of infection, because worms cause substantial mechanical damage as they burrow through host tissue.¹³ The same mucus overproduction, barrier changes, and smooth muscle hyperactivity that plague someone with asthma are, in the context of a gut full of hookworms, a survival mechanism. Allergic disease is essentially this ancient anti-parasite program triggered by harmless substances like pollen or dust mite proteins.

Macrophage Polarization and Tissue Repair

Beyond their effects on epithelial and smooth muscle cells, IL-4 and IL-13 profoundly reshape the behavior of macrophages, the immune system’s versatile scavenger cells. When macrophages encounter IL-4 or IL-13, they shift into what is called an alternatively activated state, sometimes labeled M2 polarization. These alternatively activated macrophages take on a metabolic and functional profile quite different from the classically activated macrophages that fight bacterial infections. Instead of producing aggressive inflammatory molecules, they promote wound healing, produce anti-inflammatory signals, and help remodel the extracellular matrix.¹⁴

This tissue-repair function is genuinely useful after parasite-induced damage or ordinary wounds. But when IL-4 and IL-13 signaling is chronically elevated, as it is in persistent allergic disease, macrophage-driven repair processes overshoot. That overshooting is one pathway to fibrosis.

Fibrosis and Chronic Tissue Remodeling

IL-13 in particular is a potent driver of fibrosis, the excessive deposition of collagen and other structural proteins that stiffens and scars tissue. In the skin, IL-13 directly activates fibroblasts to proliferate and produce type I collagen, and fibroblasts derived from keloid scars respond to IL-13 with a faster and larger collagen output than normal skin fibroblasts.¹⁵ In the airways of asthma patients, IL-13 boosts collagen production by airway fibroblasts through a chain of events involving the enzyme MMP-2 and the growth factor TGF-β1.¹⁶ This subepithelial fibrosis thickens the airway walls and contributes to the progressive, partially irreversible loss of lung function seen in long-standing asthma.

Lab studies have confirmed the dose-dependent nature of this effect: treating fibroblasts with IL-13 increased collagen gene expression by roughly threefold and collagen protein levels by about 72 percent compared to untreated controls.¹⁷ The STAT6 signaling pathway, the same one activated by both IL-4 and IL-13 through their shared receptor chain, is central to this fibrotic response.

Atopic Dermatitis and the Skin Microbiome

Atopic dermatitis (eczema) is one of the diseases where IL-4 and IL-13 do the most visible damage. The same barrier-weakening, inflammation-driving effects they produce in the airways play out in the skin, thinning the protective outer layer and inviting colonization by harmful bacteria. Staphylococcus aureus, a bacterium that thrives in inflamed, barrier-compromised skin, is a near-universal finding in eczema flares.

When researchers treated atopic dermatitis patients with dupilumab, a drug that blocks IL-4Rα and therefore shuts down signaling from both IL-4 and IL-13, they observed not only clinical improvement but a measurable shift in the skin microbiome. Staphylococcus aureus abundance dropped, and overall microbial diversity increased, with these microbiome changes correlating with decreases in type 2 inflammatory markers.¹⁸ This finding neatly illustrates how IL-4 and IL-13 create a disease environment that extends beyond just inflammation: by undermining barrier function and skewing the local immune response, they reshape the ecosystem of microbes living on the skin.

Built-In Brakes on IL-13 Signaling

The body does not leave a powerful inflammatory pathway like IL-13 completely unchecked. One of the more elegant control mechanisms is a decoy receptor called IL-13Rα2. Unlike the functional IL-13Rα1 chain that forms part of the signaling receptor, IL-13Rα2 binds IL-13 with very high affinity but does not transmit a signal. It acts as a molecular sponge, soaking up IL-13 and preventing it from activating STAT6.¹⁹ This decoy receptor essentially limits how much IL-13 is available to drive inflammation and fibrosis at any given tissue site.

IL-13Rα2 is expressed in various tissues and can be either membrane-bound or released in a soluble form. Its existence means that the net effect of IL-13 at a particular location depends not just on how much IL-13 is present but also on how much decoy receptor is there to intercept it. Interestingly, IL-4 does not bind this decoy receptor, which adds another layer of functional distinction between the two cytokines.

Biologic Therapies That Target the IL-4 and IL-13 Axis

The deep involvement of IL-4 and IL-13 in allergic disease has made them prime therapeutic targets. Dupilumab, which blocks the IL-4Rα chain shared by both cytokines, was the first biologic to exploit this vulnerability. Because IL-4Rα is required for both IL-4 and IL-13 to complete their receptor complexes, a single antibody effectively silences signaling from both. Dupilumab is approved for asthma, atopic dermatitis, and chronic sinusitis with nasal polyps, among other type 2 inflammatory conditions.²⁰

Beyond dupilumab, a range of newer agents target different points in the pathway. Some are antibodies directed specifically at IL-13 itself rather than the receptor, while others go after the intracellular JAK enzymes that relay the signal once the receptor is engaged.²¹ The clinical success of these drugs has validated decades of basic research into IL-4 and IL-13 biology. It has also confirmed something that was debated for years: blocking IL-13 alone is not always sufficient, and dual blockade of both cytokines tends to produce broader suppression of type 2 inflammation. The existence of overlapping but non-identical functions means you often need to shut down both to get a robust clinical effect.

Roles in Fat Metabolism and Energy Balance

In a surprising twist from their inflammatory reputation, IL-4 and IL-13 also play constructive roles in metabolic regulation. In adipose tissue, these cytokines are part of an anti-inflammatory circuit involving alternatively activated macrophages and eosinophils that helps maintain insulin sensitivity and glucose tolerance.²²

One specific mechanism involves beige fat, a type of adipose tissue that burns energy to produce heat rather than storing it. Eosinophil-derived IL-4 and innate lymphoid cell-derived IL-13 stimulate precursor cells in fat tissue to differentiate into beige adipocytes. Mice lacking IL-4 and IL-13, or those missing the IL-4Rα chain, show impaired beige fat formation and reduced ability to maintain body temperature during cold exposure.²³ These metabolic roles are a reminder that type 2 immunity is not inherently pathological. In its normal state, this branch of the immune system contributes to everyday physiological maintenance in tissues far removed from any allergen or parasite.

Cognitive Function and the Brain

Perhaps the most unexpected role for IL-13 is in learning and memory. Mice lacking IL-13 show significant impairments in working memory and reduced reference memory on standard cognitive tests. The effect appears to be mediated through astrocytes, the support cells in the brain that help regulate neuronal signaling. IL-13 produced by immune cells in the meninges (the membranes surrounding the brain) stimulates astrocytes in the hippocampus, the brain’s memory center.²⁴ IL-4 had previously been linked to similar cognitive functions, and the finding that IL-13 participates too suggests that type 2 immune signaling in the brain is a broader phenomenon than anyone initially suspected.

This research is still in early stages, mostly from animal models, and no one is prescribing IL-13 for memory enhancement. But it does raise interesting questions about what happens to cognitive function during aggressive immune suppression with drugs like dupilumab, and about why some patients on biologic therapies report subtle neurological side effects. The connection between immune molecules and brain function is one of the more active frontiers in neuroimmunology.

IL-4, IL-13, and Cancer

The relationship between these cytokines and cancer is complex and, in many cases, unfavorable. IL-4, IL-13, and their shared type II receptor are expressed by several types of solid tumors and play roles in promoting tumor growth, immune evasion, and progression. In the tumor microenvironment, these cytokines can shift the local immune balance away from the aggressive, tumor-killing type 1 responses and toward the tissue-repair and immune-dampening type 2 profile, essentially giving the tumor a more permissive environment to grow in.²⁵

At the same time, the overexpression of IL-13 receptors on certain tumor types has been explored as a potential drug-delivery target, a way to direct cytotoxic agents specifically to cancer cells that display these receptors in abundance. The decoy receptor IL-13Rα2, mentioned earlier as a natural brake on IL-13 signaling, is highly expressed in some glioblastoma tumors, and researchers have used it as a homing signal for engineered therapies. The duality is striking: the same receptor system that fuels allergic misery and, in some contexts, helps tumors evade immune detection could also serve as the address label for precision cancer treatments.